最新 100 件のみ表示中(全 3616 件)。 古い resummary は各 Summary YAML の
synthesis_historyで確認できます。
2026-06-23 (1 papers)
- Costa-Silva et al. NatCellBiol 2015 — Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver (Basic-Extracellular vesicles)
2026-06-22 (1 papers)
- Lipson et al. NatMed 2012 — Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies (Clinical-NSCLC-Driver-Other)
2026-06-18 (2 papers)
- Chaft et al. JAMA 2026 — Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial (Clinical-NSCLC-Driver negative)
- Sethakorn et al. Cancer 2026 — The future promise of antibody-drug conjugates in extensive-stage small cell lung cancer (Clinical-SCLC)
2026-06-17 (2 papers)
- FDA 2011 — Guidance for Industry: Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics (Clinical-Methodology)
- Jolliet et al. Thorax 1997 — Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predict… (Clinical-Respiratory diseases)
2026-06-16 (10 papers)
- Vilarino et al. MolCancer 2026 — NSCLC Brain Metastases Exhibit Reduced HLA-I Antigen Presentation Machinery and Immune Evasion Independent of IFNγ Si… (Basic-Brain metastasis)
- Bianca et al. NatRevImmunol 2026 — CRISPR screen reveals regulators of age-associated cd8+ t cell dysfunction in cancer (Basic-Immunotherapy)
review - Barrington et al. JClinOncol 2014 — Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Mali… (Basic-Others)
review - Roeder et al. NatMed 2006 — Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications (Basic-Others)
- Iyoda et al. Cancer 2001 — Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocri… (Clinical-NEC)
- Heijboer et al. LungCancer 2025 — Treatment outcomes in patients with stage IV large cell neuroendocrine carcinoma: a nationwide registry study (Clinical-NEC)
- Aprile et al. OncoTargetsTher 2014 — Ramucirumab: preclinical research and clinical development (Clinical-NSCLC-Driver negative)
- DiStasi et al. NEnglJMed 2011 — Inducible apoptosis as a safety switch for adoptive cell therapy (Clinical-Novel modalities)
- Zhu et al. CancerRes 2021 — Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis (Clinical-SCLC)
- Radovich et al. CancerCell 2018 — The Integrated Genomic Landscape of Thymic Epithelial Tumors (Clinical-Thymic)
2026-06-15 (84 papers)
- Farber et al. NatRevImmunol 2014 — Human memory T cells: generation, compartmentalization and homeostasis (Basic-Immunotherapy)
review - Elahi et al. NatRevImmunol 2026 — Immune regulation by erythroid cells how erythroid progenitor cells and mature red blood cells shape immunity (Basic-Immunotherapy)
review - Donia et al. ScandJImmunol 2012 — Characterization and comparison of ‘standard’ and ‘young’ tumour-infiltrating lymphocytes for adoptive cell therapy a… (Basic-Immunotherapy)
- Batool et al. CellRepMed 2023 — Extrinsic and intrinsic preanalytical variables affecting liquid biopsy in cancer (Basic-Liquid-biopsy)
review - Song et al. NatBiomedEng 2022 — Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics (Basic-Liquid-biopsy)
- Chen et al. NatMed 1996 — Microsatellite alterations in plasma DNA of small cell lung cancer patients (Basic-Liquid-biopsy)
- Bronte et al. NatCommun 2016 — Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards (Basic-Neutrophil and myeloid cell)
- Youn et al. SciAdv 2023 — Neutrophil-intrinsic TNF receptor signaling orchestrates host defense against Staphylococcus aureus (Basic-Neutrophil and myeloid cell)
- Alkan et al. bioRxiv 2026 — S100A9-dependent CXCR2hi neutrophils mediate systemic immune suppression and (Basic-Neutrophil and myeloid cell)
- Wang et al. CancerDiscov 2018 — A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor (Basic-Oncogene and genetics)
- Koboldt et al. Cell 2013 — The next-generation sequencing revolution and its impact on genomics (Basic-Oncogene and genetics)
- Keun et al. MolCell 2023 — RBM39: A druggable metabolic sensor linking RNA splicing, transcriptional regulation, and metabolic reprogramming in … (Basic-Oncogene and genetics)
- Shendure et al. Nature 2017 — DNA sequencing at 40: past, present and future (Basic-Oncogene and genetics)
- Yang et al. ProteinCell 2022 — Emerging roles of spliceosome in cancer and immunity (Basic-Oncogene and genetics)
review - Weinstein et al. Science 2002 — Addiction to oncogenes—the Achilles heel of cancer (Basic-Oncogene and genetics)
- Graw et al. ACSOmega 2020 — proteiNorm - A User-Friendly Tool for Normalization and Analysis of TMT and Label-Free Protein Quantification (Basic-Others)
- ODwyer et al. BMJOncol 2026 — Treatment of oligometastatic lung cancers new data, new drivers, new approaches (Basic-Others)
review - Liang et al. CancerCell 2026 — Spatial biomarker discovery via interpretable semantic learning in histopathology (Basic-Others)
- Glickman et al. Cell 2012 — Converting cancer therapies into cures: lessons from infectious diseases (Basic-Others)
- Hinterleitner et al. Cell 2026 — Senescence in cancer: Hallmarks, paradoxes, and therapeutic promise (Basic-Others)
- Madsen et al. DevCell 2010 — Cancer dissemination—lessons from leukocytes (Basic-Others)
- Sharp et al. FrontImmunol 2023 — Experimental procedures for flow cytometry of wild-type mouse brain: a systematic review (Basic-Others)
review - Laisne et al. NatRevCancer 2025 — Epigenomic heterogeneity as a source of tumour evolution (Basic-Others)
review - Michor et al. Nature 2005 — Dynamics of chronic myeloid leukaemia (Basic-Others)
- Network et al. Nature 2012 — Comprehensive molecular characterization of human colon and rectal cancer (Basic-Others)
- Lefrancais et al. Nature 2017 — The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors (Basic-Others)
- La et al. Nature 2018 — RNA velocity of single cells (Basic-Others)
- Lu et al. Nature 2026 — Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer (Basic-Others)
- Rosin et al. STARProtoc 2021 — Live-cell imaging of microglial interactions with radial glia in transgenic embryonic mouse brains using slice culture (Basic-Others)
- Grout et al. CancerDiscov 2022 — Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors (Basic-Tumor microenvironment)
- Nigri et al. CancerDiscov 2026 — Myofibroblasts induce neuroplasticity to promote pancreatic inflammation and cancer progression (Basic-Tumor microenvironment)
- Devesa et al. IntJCancer 2005 — International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising (Clinical-Epidemiology)
- Yano et al. JThoracCardiovascSurg 1994 — The first site of recurrence after complete resection in non-small-cell carcinoma of the lung. Comparison between pN0… (Clinical-Epidemiology)
- Adams et al. Lancet 2023 — Lung cancer screening (Clinical-Epidemiology)
- Maas et al. NatMed 2026 — Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure (Clinical-Epidemiology)
- Gu et al. Bioinformatics 2016 — Complex heatmaps reveal patterns and correlations in multidimensional genomic data (Clinical-Methodology)
- Udagawa et al. CancerSci 2020 — Feasibility and utility of transbronchial cryobiopsy in precision medicine for lung cancer: Prospective single-arm study (Clinical-Methodology)
- An et al. JClinPharmacol 2020 — Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds (Clinical-Methodology)
- Ou et al. JThoracOncol 2010 — Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK transloc… (Clinical-NSCLC-ALK)
- Gemma et al. JThoracOncol 2019 — Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment Wit… (Clinical-NSCLC-ALK)
- Chino et al. LungCancer 2015 — Successful treatment with alectinib after crizotinib-induced interstitial lung disease. (Clinical-NSCLC-ALK)
- Tang et al. AnnOncol 2017 — Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical … (Clinical-NSCLC-Driver negative)
- NSCLCMetaAnalyses et al. BMJ 1995 — Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomi… (Clinical-NSCLC-Driver negative)
review - Dummer et al. JAMAOncol 2020 — Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review (Clinical-NSCLC-Driver negative)
review - Okamoto et al. JClinOncol 2010 — Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients w… (Clinical-NSCLC-Driver negative)
- Kim et al. Cell 2020 — Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients (Clinical-NSCLC-Driver-Other)
- Fernandez-Cuesta et al. ClinCancerRes 2015 — Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer (Clinical-NSCLC-Driver-Other)
- Ruge et al. ClinCancerRes 2026 — Molecular and clinical characteristics of patients with NSCLC harboring KRAS Q61 mutations to assess therapeutic resp… (Clinical-NSCLC-Driver-Other)
- He et al. JNatlCancerCent 2026 — Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain (Clinical-NSCLC-Driver-Other)
- Nakaoku et al. NatCommun 2018 — A secondary RET mutation in the activation loop conferring resistance to vandetanib (Clinical-NSCLC-Driver-Other)
- Planchard et al. AnnOncol 2015 — EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients (Clinical-NSCLC-EGFR)
- Stephens et al. Nature 2004 — Intragenic ERBB2 kinase mutations in tumours (Clinical-NSCLC-HER2)
- Zhou et al. CellRepPhysSci 2025 — Challenges and opportunities for lysosome-targeting chimeras (Clinical-Novel modalities)
- Kershaw et al. ClinCancerRes 2006 — A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer (Clinical-Novel modalities)
- Curran et al. JClinOncol 2015 — Chimeric antigen receptor T cells for cancer immunotherapy (Clinical-Novel modalities)
- Grupp et al. NEnglJMed 2013 — Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. (Clinical-Novel modalities)
- Tran et al. NEnglJMed 2016 — T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer (Clinical-Novel modalities)
- King-Peoples et al. NatCancer 2021 — Splitting signals drives CARs further. (Clinical-Novel modalities)
- Kong et al. NatCancer 2026 — Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy (Clinical-Novel modalities)
- Blass et al. NatRevClinOncol 2021 — Advances in the development of personalized neoantigen-based therapeutic cancer vaccines (Clinical-Novel modalities)
review - Nicholas et al. npjPrecisOncol 2026 — Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancer (Clinical-Novel modalities)
- Zhu et al. IntJRadiatOncolBiolPhys 2026 — Low-dose SBRT-based radiotherapy followed by pembrolizumab and chemotherapy for potentially resectable NSCLC A phase ib (Clinical-Others)
- Hao et al. CancerCommun(Lond) 2026 — Serplulimab plus chemotherapy, with or without HLX04, versus chemotherapy as first-line treatment for nonsquamous NSCLC (Clinical-SCLC)
- Schaff et al. CancerRes 2021 — Fragmentation of Small-Cell Lung Cancer Regulatory States in Heterotypic Microenvironments (Clinical-SCLC)
- Kelly et al. ClinCancerRes 2001 — Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-… (Clinical-SCLC)
- Rea et al. EurJCardiothoracSurg 1998 — Long-Term Results of Surgery and Chemotherapy in Small Cell Lung Cancer (Clinical-SCLC)
- Yana et al. InvestNewDrugs 2007 — Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japa… (Clinical-SCLC)
- Smith et al. JClinOncol 1987 — Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer (Clinical-SCLC)
- Montella et al. JClinOncol 2013 — Evaluation of Elderly Patients With Extended-Disease Small-Cell Lung Cancer (Clinical-SCLC)
- Hahn et al. IntJClinOncol 2011 — A case of acute aortic thrombosis after cisplatin-based chemotherapy. (Clinical-Supportive care)
- Smith et al. JAMA 2013 — Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripher… (Clinical-Supportive care)
- vonHaehling et al. JCachexiaSarcopeniaMuscle 2014 — Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014 (Clinical-Supportive care)
- Aaronson et al. JNatlCancerInst 1993 — The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in inter… (Clinical-Supportive care)
- Koizumi et al. AmJClinOncol 2002 — Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosph… (Clinical-Thymic)
- Hirai et al. AnticancerRes 2014 — Results of S-1-based chemotherapy for platinum (and antrathycline)-refractory advanced thymic carcinoma (Clinical-Thymic)
- Girard et al. ESMOOpen 2023 — Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the… (Clinical-Thymic)
- Engels et al. IntJCancer 2003 — Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. (Clinical-Thymic)
- Riely et al. JNatlComprCancNetw 2025 — Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology (Clinical-Thymic)
review - Napieralska et al. JThoracDis 2018 — Primary mediastinal seminoma (Clinical-Thymic)
- Ruffini et al. JThoracOncol 2023 — The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a S… (Clinical-Thymic)
- Cybulska-Stopa et al. CaseRepOncol 2019 — Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy - Interrupt or Continue Treatment - The Role of Immunohistoc… (Clinical-irAE)
- Michot et al. EurJCancer 2017 — Immune-related bone marrow failure following anti-PD1 therapy. (Clinical-irAE)
- Michot et al. EurJCancer 2020 — The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an obse… (Clinical-irAE)
- Tison et al. NatRevRheumatol 2022 — Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. (Clinical-irAE)